The Potential Health Risks of GLP-1 Medications: What Patients Should Know
GLP-1 receptor agonists (such as ozempic) have gained widespread attention for their ability to reduce appetite and support weight loss. However, like all medications, GLP-1’s are not risk-free — and understanding potential downsides is essential for informed decision-making.
1. Gastrointestinal Side Effects (Most Common)
GLP-1 medications slow gastric emptying and reduce appetite signaling, which frequently leads to GI symptoms, including:
-
Nausea
-
Vomiting
-
Diarrhea or constipation
-
Abdominal discomfort
-
Early satiety
While often described as “temporary,” symptoms can persist or become severe enough to cause dehydration, electrolyte imbalances, or medication discontinuation in some patients.
2. Loss of Lean Muscle Mass
Rapid weight loss — especially without resistance training or adequate protein intake — increases the risk of:
-
Muscle loss
-
Strength decline
-
Reduced metabolic rate
Research suggests a meaningful portion of weight lost on GLP-1 therapy may come from lean tissue, not just fat, which can:
-
Impair physical function
-
Increase frailty risk in older adults
-
Make long-term weight maintenance more difficult
3. Gallbladder Disease
GLP-1 use has been associated with an increased risk of:
-
Gallstones
-
Gallbladder inflammation (cholecystitis)
This risk appears related to rapid weight loss, which alters bile composition and gallbladder motility.
4. Pancreatitis (Rare but Serious)
Although uncommon, GLP-1 medications carry warnings for acute pancreatitis. Symptoms may include:
-
Severe abdominal pain
-
Persistent nausea or vomiting
Patients with a history of pancreatitis or pancreatic disease should be evaluated carefully before initiation.
5. Potential Thyroid Concerns
In rodent studies, GLP-1 receptor agonists were associated with medullary thyroid carcinoma (MTC). While this has not been conclusively shown in humans, GLP-1s are contraindicated in patients with:
-
Personal or family history of MTC
-
Multiple endocrine neoplasia syndrome type 2 (MEN2)
6. Nutrient Inadequacy & Undereating
Because GLP-1s significantly suppress appetite, some individuals unintentionally consume:
-
Too few calories
-
Insufficient protein
-
Inadequate micronutrients
Over time, this can contribute to:
-
Fatigue
-
Hair loss
-
Muscle wasting
-
Nutrient deficiencies
7. Psychological & Behavioral Risks
GLP-1 medications do not address the behavioral drivers of overeating, such as:
-
Emotional eating
-
Stress-related eating
-
Habitual or environmental triggers
Without behavioral support, patients may:
-
Struggle when medication is paused or discontinued
-
Experience rapid weight regain
-
Develop an overreliance on medication rather than skills
8. Weight Regain After Discontinuation
Evidence consistently shows that weight regain is common after stopping GLP-1 therapy, particularly when lifestyle habits are not established. This reinforces the concept that obesity is a chronic condition requiring ongoing care, not a short-term pharmaceutical fix.
Putting Risk in Perspective
GLP-1 medications are not inherently “good” or “bad.” They can be useful tools when appropriately prescribed, monitored, and paired with:
-
Nutrition guidance
-
Physical activity (especially resistance training)
-
Long-term behavior change strategies
However, when used as a stand-alone solution, risks increase and sustainability decreases.
Bottom Line
GLP-1 medications can support weight loss and metabolic health — but they are not without potential health risks, particularly when lifestyle, nutrition, and muscle preservation are overlooked.
The safest and most effective approach is medically supervised GLP-1 therapy combined with structured lifestyle intervention, emphasizing long-term health, not just short-term weight loss.
Have a healthy day!
Kevin Grodnitzky, MS, RDN
The Weight Loss Dietitian